logo-loader
RNS
AstraZeneca PLC

AstraZeneca PLC - EMTN programme update - publication of Prospectus

RNS Number : 6580Z
AstraZeneca PLC
25 May 2021
 

 

25 May 2021 07:00 BST

 

EMTN programme update: publication of Prospectus 

 

Following an update by AstraZeneca PLC ("AstraZeneca") of its Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the Financial Conduct Authority and is available for viewing:

 

Base Prospectus for the AstraZeneca and AstraZeneca Finance LLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

 

AstraZeneca Finance LLC has been added as an issuer to the EMTN programme for 2021. Securities under the programme may therefore be issued by either AstraZeneca or AstraZeneca Finance LLC, depending on AstraZeneca's requirements. Any securities issued by AstraZeneca Finance LLC will be guaranteed by AstraZeneca.

 

The last drawdown under the EMTN programme was in 2016.

 

To view the full document, please paste the following URL into the address bar of your browser.
 

http://www.rns-pdf.londonstockexchange.com/rns/6580Z_1-2021-5-24.pdf

 

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

AstraZeneca contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PDIFFFLLEVISFIL
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read